TapewireFind a company

person · Reporting owner

Dearen Danny L.

Disclosed activity across 3 companies

Tapewire entity
44223
SEC CIK
0001756438

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Beta Bionics, Inc.BBNX · Entity 2350DirectorMay 21, 2026May 26, 2026
InspireMD, Inc.NSPR · Entity 7318DirectorJanuary 14, 2026January 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Beta Bionics, Inc.

Report date May 21, 2026 · Filed May 26, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect32,209 Reported balance After 2026-05-21 transaction · row 1
1 source row

Row 1 · 2026-05-21 · Grant · Acquired 16,965 · Balance 32,209

F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

InspireMD, Inc.

Report date January 14, 2026 · Filed January 16, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect102,047 Reported balance After 2026-01-14 transaction · row 1
1 source row

Row 1 · 2026-01-14 · Grant · Acquired 44,030 · Balance 102,047

F1: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Axonics, Inc.

Report date September 29, 2023 · Filed October 03, 2023

Section 16 reporting ended · disclosed 2023-10-03. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect23,777 Ending reported balance After 2023-09-29 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2023-09-29 · Exercise / conversion · Acquired 11,250 · Balance 31,452

Row 2 · 2023-09-29 · Sale · Disposed 7,675 · Balance 23,777

F1: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F2: This transaction was executed in multiple trades at prices ranging from $56.51 to $57.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2023-09-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2023-09-29 · Exercise / conversion · Disposed 11,250 · Balance 0

F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023. The units represented here are pro-rated through the date of separation.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F2: This transaction was executed in multiple trades at prices ranging from $56.51 to $57.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023. The units represented here are pro-rated through the date of separation.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 21, 2026 Filed May 26, 2026 22:00 UTC Beta Bionics, Inc. BBNX · Entity 2350 GrantCommon Stock 16,965 $0.00 $0.00
Disclosure

SEC source: 0001756438-26-000003 · form4-05262026_060527.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,209

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

Read SEC document
January 14, 2026 Filed Jan 16, 2026 23:09 UTC InspireMD, Inc. NSPR · Entity 7318 GrantCommon Stock 44,030 $0.00 $0.00
Disclosure

SEC source: 0001493152-26-002664 · ownership.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,047

F1 · shares: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.

Read SEC document
January 13, 2026 Filed Jan 15, 2026 01:30 UTC Beta Bionics, Inc. BBNX · Entity 2350 GrantCommon Stock 3,997 $0.00 $0.00
Disclosure

SEC source: 0001756438-26-000002 · form4-01142026_080101.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,244

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

Read SEC document
March 15, 2025 Filed Mar 19, 2025 00:00 UTC Beta Bionics, Inc. BBNX · Entity 2350 GrantCommon Stock 11,247 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-008535 · form4-03182025_080306.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,247

F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

Read SEC document
September 29, 2023 Filed Oct 3, 2023 19:37 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionPerformance-Based Restricted Stock Units · Derivative 11,250 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-007190 · primarydocument.xml · derivative · entry 3

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023. The units represented here are pro-rated through the date of separation.

F3 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023. The units represented here are pro-rated through the date of separation.

F3 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023. The units represented here are pro-rated through the date of separation.

Read SEC document
September 29, 2023 Filed Oct 3, 2023 19:37 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 7,675 $56.87 $436,490.30
Disclosure

SEC source: 0001562180-23-007190 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,777

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F2 · price: This transaction was executed in multiple trades at prices ranging from $56.51 to $57.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
September 29, 2023 Filed Oct 3, 2023 19:37 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 11,250 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-007190 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,452

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 26, 2023 Filed May 31, 2023 20:01 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 300 $50.14 $15,042.00
Disclosure

SEC source: 0001562180-23-004641 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,202

F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

Read SEC document
May 26, 2023 Filed May 31, 2023 20:01 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 7,699 $49.44 $380,603.91
Disclosure

SEC source: 0001562180-23-004641 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,502

F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $49.09 to $50.025. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 21, 2023 Filed Apr 25, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Options (Right to buy) · Derivative 13,208 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001562180-23-003685 · primarydocument.xml · derivative · entry 4

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,208 shares

Expires 2029-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 1, 2023, provided the reporting person remains in continuous service on each vesting date.

Read SEC document
April 21, 2023 Filed Apr 25, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 9,637 $60.50 $583,074.16
Disclosure

SEC source: 0001562180-23-003685 · primarydocument.xml · nonDerivative · entry 3

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,201

F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $60.22 to $61.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 21, 2023 Filed Apr 25, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 10,363 $59.93 $621,062.88
Disclosure

SEC source: 0001562180-23-003685 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,838

F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $59.22 to $60.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 21, 2023 Filed Apr 25, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 13,208 $14.19 $187,421.52
Disclosure

SEC source: 0001562180-23-003685 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,201

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 20, 2023 Filed Apr 24, 2023 20:35 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Options (Right to buy) · Derivative 2,001 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001562180-23-003669 · primarydocument.xml · derivative · entry 3

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,208

Underlying: Common Stock · 2,001 shares

Expires 2029-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 1, 2023, provided the reporting person remains in continuous service on each vesting date.

Read SEC document
April 20, 2023 Filed Apr 24, 2023 20:35 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 2,001 $60.01 $120,072.61
Disclosure

SEC source: 0001562180-23-003669 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,993

F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
April 20, 2023 Filed Apr 24, 2023 20:35 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 2,001 $14.19 $28,394.19
Disclosure

SEC source: 0001562180-23-003669 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:24 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Options (Right to buy) · Derivative 2,899 $0.00 Strike: $1.63 $0.00
Disclosure

SEC source: 0001562180-23-003425 · primarydocument.xml · derivative · entry 8

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,899 shares

Expires 2028-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:24 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Options (Right to buy) · Derivative 5,468 $0.00 Strike: $25.82 $0.00
Disclosure

SEC source: 0001562180-23-003425 · primarydocument.xml · derivative · entry 7

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,032

Underlying: Common Stock · 5,468 shares

Expires 2029-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 1, 2023, provided the reporting person remains in continuous service on each vesting date.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:24 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Options (Right to buy) · Derivative 6,633 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001562180-23-003425 · primarydocument.xml · derivative · entry 6

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,209

Underlying: Common Stock · 6,633 shares

Expires 2029-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 1, 2023, provided the reporting person remains in continuous service on each vesting date.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:24 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 7,802 $55.68 $434,403.66
Disclosure

SEC source: 0001562180-23-003425 · primarydocument.xml · nonDerivative · entry 5

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,993

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $55.49 to $55.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:24 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 7,198 $54.83 $394,699.45
Disclosure

SEC source: 0001562180-23-003425 · primarydocument.xml · nonDerivative · entry 4

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,795

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $54.49 to $55.4839. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:24 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 2,899 $1.63 $4,725.37
Disclosure

SEC source: 0001562180-23-003425 · primarydocument.xml · nonDerivative · entry 3

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,993

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:24 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 5,468 $25.82 $141,183.76
Disclosure

SEC source: 0001562180-23-003425 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,094

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 20:24 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 6,633 $14.19 $94,122.27
Disclosure

SEC source: 0001562180-23-003425 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,626

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 01, 2023 Filed Feb 2, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 2,772 $61.02 $169,136.35
Disclosure

SEC source: 0001562180-23-000874 · primarydocument.xml · nonDerivative · entry 6

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,993

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F5 · price: This transaction was executed in multiple trades at prices ranging from $60.85 to $61.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 01, 2023 Filed Feb 2, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 474 $60.43 $28,646.05
Disclosure

SEC source: 0001562180-23-000874 · primarydocument.xml · nonDerivative · entry 5

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,765

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F4 · price: This transaction was executed in multiple trades at prices ranging from $59.85 to $60.845. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionPerformance-Based Restricted Stock Units · Derivative 20,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000874 · primarydocument.xml · derivative · entry 10

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023.

F9 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023.

F9 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2023, and provided the reporting person remains in continuous service through January 31, 2023.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionPerformance-Based Restricted Stock Units · Derivative 5,250 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000874 · primarydocument.xml · derivative · entry 9

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023.

F8 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023.

F8 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 GrantPerformance-Based Restricted Stock Units · Derivative 5,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000874 · primarydocument.xml · derivative · entry 8

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

F7 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.

F7 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.

F7 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2025, and provided the reporting person remains in continuous service through January 31, 2025.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 GrantPerformance-Based Restricted Stock Units · Derivative 15,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000874 · primarydocument.xml · derivative · entry 7

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires not disclosed

F6 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.

F6 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.

F6 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023 and provided the reporting person remains in continuous service through January 31, 2024.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 2,720 $61.12 $166,251.57
Disclosure

SEC source: 0001562180-23-000874 · primarydocument.xml · nonDerivative · entry 4

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,239

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F3 · price: This transaction was executed in multiple trades at prices ranging from $60.78 to $61.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 7,791 $61.17 $476,570.80
Disclosure

SEC source: 0001562180-23-000874 · primarydocument.xml · nonDerivative · entry 3

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,959

F1 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.

F2 · price: This transaction was executed in multiple trades at prices ranging from $60.78 to $61.595. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 25,250 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000874 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 20:06 UTC Axonics, Inc. AXNX · Entity 86004 GrantCommon Stock 5,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-23-000874 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Read SEC document
September 13, 2022 Filed Sep 15, 2022 20:03 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 656 $75.60 $49,593.60
Disclosure

SEC source: 0001562180-22-006685 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

F1 · kind: This sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Options (Right to buy) · Derivative 6,250 $0.00 Strike: $25.82 $0.00
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · derivative · entry 13

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 6,250 shares

Expires 2029-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 1, 2023, provided the reporting person remains in continuous service on each vesting date.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Options (Right to buy) · Derivative 7,047 $0.00 Strike: $14.19 $0.00
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · derivative · entry 12

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,223

Underlying: Common Stock · 7,047 shares

Expires 2029-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 1, 2023, provided the reporting person remains in continuous service on each vesting date.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Options (Right to buy) · Derivative 20,545 $0.00 Strike: $1.63 $0.00
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · derivative · entry 11

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,545 shares

Expires 2028-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Options (Right to buy) · Derivative 2,044 $0.00 Strike: $1.32 $0.00
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · derivative · entry 10

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,044 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on May 22, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of May 22, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Options (Right to buy) · Derivative 1,616 $0.00 Strike: $1.32 $0.00
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · derivative · entry 9

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,616 shares

Expires 2027-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on July 5, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of July 5, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 6,960 $72.19 $502,429.18
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · nonDerivative · entry 8

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,156

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $71.98 to $72.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 16,280 $71.26 $1,160,173.04
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · nonDerivative · entry 7

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,116

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $70.96 to $71.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 26,760 $70.33 $1,881,921.08
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · nonDerivative · entry 6

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,396

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $69.96 to $70.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 6,250 $25.82 $161,375.00
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · nonDerivative · entry 5

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,156

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 7,047 $14.19 $99,996.93
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · nonDerivative · entry 4

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,906

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 20,545 $1.63 $33,488.35
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · nonDerivative · entry 3

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,859

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 2,044 $1.32 $2,698.08
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · nonDerivative · entry 2

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:34 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionCommon Stock 1,616 $1.32 $2,133.12
Disclosure

SEC source: 0001562180-22-006102 · primarydocument.xml · nonDerivative · entry 1

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,270

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 19:45 UTC Axonics, Inc. AXNX · Entity 86004 Exercise / conversionStock Options (Right to buy) · Derivative 12,329 $0.00 Strike: $25.82 $0.00
Disclosure

SEC source: 0001562180-22-002348 · primarydocument.xml · derivative · entry 5

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,343

Underlying: Common Stock · 12,329 shares

Expires 2029-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 1, 2023, provided the reporting person remains in continuous service on each vesting date.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 19:45 UTC Axonics, Inc. AXNX · Entity 86004 SaleCommon Stock 10,564 $58.11 $613,913.13
Disclosure

SEC source: 0001562180-22-002348 · primarydocument.xml · nonDerivative · entry 4

Dearen Danny L. · CIK 0001756438 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,654

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $57.85 to $58.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.